Form 4: Director Sells STOK Shares Under 10b5-1 Plan

Stoke Therapeutics Director Adrian R. Krainer sold 40,472 shares of common stock for approximately $29.72 per share under a pre-arranged trading plan.

Summary

• Adrian R. Krainer, a Director of Stoke Therapeutics, Inc. (STOK), sold 40,472 shares of common stock.
• The transaction occurred on November 24, 2025.
• The shares were sold at a weighted average price of $29.7173 per share, with individual sales ranging from $29.50 to $30.12.
• Following this transaction, Krainer directly beneficially owns 323,774 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2025.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which typically carries less negative sentiment than an unscheduled sale.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.

Negatives

• A director selling a significant number of shares could be perceived negatively by some investors, even if pre-planned.

Future Outlook

NA

Industry Context

This Form 4 reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May view the director's sale of shares as a slight negative, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

The Form 4 reports a routine insider sale by a director under a pre-arranged 10b5-1 plan. This type of transaction is generally not considered a strong signal for future stock performance as it's often for personal financial planning rather than based on new company developments. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Sale, Director, Adrian R. Krainer, 10b5-1 Plan, Equity Transaction